Dr. Julie Gralow, Executive Vice President and Chief Medical Officer of ASCO (American Society of Medical Oncology,) the largest society for oncologists around the world, shares her career journey until she assumed the post of ASCO-CMO during the COVID-19 pandemic.
Julie is a pioneer in global oncology and a world-renowned leader in breast cancer, being an innovator and a researcher at the Fred Hutchinson Cancer Center in Seattle for over 20 years. Her impact on the field is second to none.
Dr. Gralow discusses how ASCO attempts to address hot and controversial issues in oncology in a timely and effective manner. We go over the current chemotherapy shortage and abortion rights for patients with cancer, among other topics.
This episode is a must-listen for everyone in oncology; hear the most influential medical voice in oncology on behalf of our society and be inspired.
View “A Day in the Life” of Dr. Gralow at the ASCO Annual Meeting: https://twitter.com/asco/status/1671578875145461774
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
